Categories: Health

Spineway : Minutes of the General Meeting of June 4, 2025

Press release        

Ecully, June 6, 2025 – 6.00 p.m.

SPINEWAY

Minutes of the General Meeting of June 4, 2025

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2025. The number of shares held by shareholders present, represented and voting by mail was 34,383,058, representing 100% of voting rights. The quorum having been reached, the Meeting was able to proceed and deliberate normally.

Resolutions 1, 2, 3, 4, 6, 7, 8, 14, 15, 20 and 21 were approved by shareholders. Resolutions 5, 9, 10, 11, 12, 13, 16, 17, 18 and 19 were rejected.

Information relating to the Combined General Meeting is available on the Company’s website under “Investors/Regulated Information”: https://spineway.com/en/regulated-information.

Next dates:
July 30, 2025 – Half-year sales 2025

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 70% of its revenue comes from exports.
ISIN: FR001400N2P2 – ALSPW        

Contacts:

SPINEWAY

Shareholder-services line
Available Tuesday through Thursday
+33 (0)806 706 060

AELIUM

Investor relations
Solène Kennis
spineway@aelium.fr

GlobeNews Wire

Published by
GlobeNews Wire

Recent Posts

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise…

3 days ago

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

1 week ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

2 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

2 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago